In vitro versus terminal in vivo virulence factor expression.

Data represents the mean and standard deviation of the analyzed biological replicates (three replicates for in vitro; 10 Bcbva CA and 14 Bcbva CI replicates each for in vivo) for hyaluronic acid (A), protective antigen (B), and PDGA capsule (C&...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Allison M. Ferris (21011700) (author)
مؤلفون آخرون:	David G. Dawson (21011703) (author), Andrea B. Eyler (21011706) (author), John J. Yeager (21011709) (author), Jordan K. Bohannon (5999951) (author), Jeremy A. Boydston (11320726) (author), Melissa L. Krause (21011712) (author), Charles L. Balzli (21011715) (author), Victoria Wahl (11320771) (author), Tammy D. Jenkins (21011718) (author), Sherry L. Rippeon (21011721) (author), James E. Miller (147575) (author), Susan E. Miller (21011724) (author), David W. Clarke (21011727) (author), Emmanuel Manan (11320747) (author), Ashley F. Harman (21011730) (author), Kim R. Rhodes (21011733) (author), Tina M. Sweeney (21011736) (author), Heather D. Cronin (21011739) (author), Ron L. Bowman (21011742) (author), Michael P. Winpigler (21011745) (author), Heather A. Zimmerman (21011748) (author), Alec S. Hail (11320768) (author), Angelo Scorpio (2113660) (author)
منشور في:	2025
الموضوعات:	Biochemistry Medicine Microbiology Genetics Molecular Biology Immunology Infectious Diseases Virology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified virulence factors harbored virulence factor production new zealand white anthrax vaccine adsorbed quantifying temperature responses evaluate disease course currently available countermeasures disease anthrax due ci ), using bacillus cereus </ bacillus anthracis </ causes inhalational anthrax anthrax mcm efficacies without ava vaccination like disease caused cereus </ anthracis </ like disease pneumonic disease medical countermeasures exposure vaccination disease progression body temperature like plasmids zoonotic organism spores results significant increase progresses quickly possess pxo1 plasmids pxo1 often results medical countermeasure mean time exposure prophylaxis dose dependent data suggest &# 8217
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

<i>In vitro</i> versus terminal <i>in vivo</i> virulence factor expression.

مواد مشابهة